635 related articles for article (PubMed ID: 35038344)
21. Long-term course of neutralising antibodies against SARS-CoV-2 in vaccinated and unvaccinated staff and residents in a Swiss nursing home: a cohort study 2021-2022.
Perrig L; Abela IA; Banholzer N; Audigé A; Epp S; Mugglin C; Zürcher K; Egger M; Trkola A; Fenner L
Swiss Med Wkly; 2023 Dec; 153():3502. PubMed ID: 38579325
[TBL] [Abstract][Full Text] [Related]
22. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
23. Hidden fraction of Polish population immune to SARS-CoV-2 in May 2021.
Budziar W; Gembara K; Harhala M; Szymczak A; Jędruchniewicz N; Baniecki K; Pikies A; Nahorecki A; Hoffmann A; Kardaś A; Szewczyk-Dąbrowska A; Klimek T; Kaźmierczak Z; Witkiewicz W; Barczyk K; Dąbrowska K
PLoS One; 2022; 17(2):e0253638. PubMed ID: 35113873
[TBL] [Abstract][Full Text] [Related]
24. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
25. SARS-CoV-2 Delta-variant breakthrough infections in nursing home residents at midterm after Comirnaty® COVID-19 vaccination.
Torres I; Bellido-Blasco JB; Gimeno C; Burgos JS; Albert E; Moya-Malo R; Gascó-Laborda JC; Tornero A; Soriano J; Meseguer-Ferrer N; Martínez-Serrano M; Ortíz-Rambla J; Buj H; Hernández N; Peiró S; Salas D; Limón R; Vanaclocha H; Sánchez-Payá J; Díez-Domingo J; Comas I; González-Candelas F; Navarro D;
J Med Virol; 2022 Aug; 94(8):3776-3782. PubMed ID: 35445415
[TBL] [Abstract][Full Text] [Related]
26. Persisting Salivary IgG Against SARS-CoV-2 at 9 Months After Mild COVID-19: A Complementary Approach to Population Surveys.
Alkharaan H; Bayati S; Hellström C; Aleman S; Olsson A; Lindahl K; Bogdanovic G; Healy K; Tsilingaridis G; De Palma P; Hober S; Månberg A; Nilsson P; Pin E; Sällberg Chen M
J Infect Dis; 2021 Aug; 224(3):407-414. PubMed ID: 33978762
[TBL] [Abstract][Full Text] [Related]
27. Pre-Vaccine Positivity of SARS-CoV-2 Antibodies in Alberta, Canada during the First Two Waves of the COVID-19 Pandemic.
Charlton CL; Nguyen LT; Bailey A; Fenton J; Plitt SS; Marohn C; Lau C; Hinshaw D; Lutsiak C; Simmonds K; Kanji JN; Zelyas N; Lee N; Mengel M; Tipples G
Microbiol Spectr; 2021 Sep; 9(1):e0029121. PubMed ID: 34406813
[TBL] [Abstract][Full Text] [Related]
28. SARS-CoV-2 seroprevalence and antibody trends in vaccinated, multi-ethnic healthcare employees.
Beh CC; Zulkufli NS; Loh LM; Cheng KW; Choo LM; Cheah MW; Siow KW; Yon R
Trop Biomed; 2021 Dec; 38(4):552-560. PubMed ID: 35001921
[TBL] [Abstract][Full Text] [Related]
29. High-Resolution Linear Epitope Mapping of the Receptor Binding Domain of SARS-CoV-2 Spike Protein in COVID-19 mRNA Vaccine Recipients.
Nitahara Y; Nakagama Y; Kaku N; Candray K; Michimuko Y; Tshibangu-Kabamba E; Kaneko A; Yamamoto H; Mizobata Y; Kakeya H; Yasugi M; Kido Y
Microbiol Spectr; 2021 Dec; 9(3):e0096521. PubMed ID: 34756082
[TBL] [Abstract][Full Text] [Related]
30. A Multiplex Noninvasive Salivary Antibody Assay for SARS-CoV-2 Infection and Its Application in a Population-Based Survey by Mail.
Egorov AI; Griffin SM; Fuzawa M; Kobylanski J; Grindstaff R; Padgett W; Simmons S; Hallinger DR; Styles JN; Wickersham L; Sams E; Hudgens E; Wade TJ
Microbiol Spectr; 2021 Oct; 9(2):e0069321. PubMed ID: 34523986
[TBL] [Abstract][Full Text] [Related]
31. Comprehensive assessment of humoral response after Pfizer BNT162b2 mRNA Covid-19 vaccination: a three-case series.
Danese E; Montagnana M; Salvagno GL; Peserico D; Pighi L; De Nitto S; Henry BM; Porru S; Lippi G
Clin Chem Lab Med; 2021 Aug; 59(9):1585-1591. PubMed ID: 33838087
[TBL] [Abstract][Full Text] [Related]
32. SARS-CoV-2 Antibodies Are Persisting in Saliva for More Than 15 Months After Infection and Become Strongly Boosted After Vaccination.
Pinilla YT; Heinzel C; Caminada LF; Consolaro D; Esen M; Kremsner PG; Held J; Kreidenweiss A; Fendel R
Front Immunol; 2021; 12():798859. PubMed ID: 34956236
[TBL] [Abstract][Full Text] [Related]
33. Longitudinal Follow Up of Immune Responses to SARS-CoV-2 in Health Care Workers in Sweden With Several Different Commercial IgG-Assays, Measurement of Neutralizing Antibodies and CD4
Marklund E; Leach S; Nyström K; Lundgren A; Liljeqvist JÅ; Nilsson S; Yilmaz A; Andersson LM; Bemark M; Gisslén M
Front Immunol; 2021; 12():750448. PubMed ID: 34795668
[TBL] [Abstract][Full Text] [Related]
34. Comparative performance of multiplex salivary and commercially available serologic assays to detect SARS-CoV-2 IgG and neutralization titers.
Heaney CD; Pisanic N; Randad PR; Kruczynski K; Howard T; Zhu X; Littlefield K; Patel EU; Shrestha R; Laeyendecker O; Shoham S; Sullivan D; Gebo K; Hanley D; Redd AD; Quinn TC; Casadevall A; Zenilman JM; Pekosz A; Bloch EM; Tobian AAR
J Clin Virol; 2021 Dec; 145():104997. PubMed ID: 34695724
[TBL] [Abstract][Full Text] [Related]
35. Seroprevalence and levels of IgG antibodies after COVID-19 infection or vaccination.
Soeorg H; Jõgi P; Naaber P; Ottas A; Toompere K; Lutsar I
Infect Dis (Lond); 2022 Jan; 54(1):63-71. PubMed ID: 34520315
[TBL] [Abstract][Full Text] [Related]
36. Seroprevalence of anti-SARS-CoV-2 IgG antibodies pre- and post-COVID-19 vaccination in staff members of Bandar Abbas Children's Hospital.
Tariverdi M; Mohammadi H; Hassanzadeh F; Tamaddondar M
BMC Infect Dis; 2024 Feb; 24(1):253. PubMed ID: 38395759
[TBL] [Abstract][Full Text] [Related]
37. Impact of Prior Infection on SARS-CoV-2 Antibody Responses in Vaccinated Long-Term Care Facility Staff.
Gallichotte EN; Nehring M; Stromberg S; Young MC; Snell A; Daniels J; Pabilonia KL; VandeWoude S; Ehrhart N; Ebel GD
mSphere; 2022 Aug; 7(4):e0016922. PubMed ID: 35862798
[TBL] [Abstract][Full Text] [Related]
38. Assessing the Pre-Vaccination Anti-SARS-CoV-2 IgG Seroprevalence among Residents and Staff in Nursing Home in Niigata, Japan, November 2020.
Wagatsuma K; Yoshioka S; Yamazaki S; Sato R; Phyu WW; Chon I; Takahashi Y; Watanabe H; Saito R
Viruses; 2022 Nov; 14(11):. PubMed ID: 36423190
[TBL] [Abstract][Full Text] [Related]
39. Long-Term Humoral Immune Response against SARS-CoV-2 after Natural Infection and Subsequent Vaccination According to WHO International Binding Antibody Units (BAU/mL).
Ruetalo N; Flehmig B; Schindler M; Pridzun L; Haage A; Reichenbächer M; Kirchner T; Kirchner T; Klingel K; Ranke MB; Normann A
Viruses; 2021 Nov; 13(12):. PubMed ID: 34960605
[TBL] [Abstract][Full Text] [Related]
40. Immune Response 5-7 Months after Vaccination against SARS-CoV-2 in Elderly Nursing Home Residents in the Czech Republic: Comparison of Three Vaccines.
Martínek J; Tomášková H; Janošek J; Zelená H; Kloudová A; Mrázek J; Ježo E; Král V; Pohořská J; Šturcová H; Maďar R
Viruses; 2022 May; 14(5):. PubMed ID: 35632827
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
